GRI
GRI Bio, Inc.
Price Chart
Latest Quote
$1.86
-0.01 (-0.53%)
Current Price
| Previous Close | $1.87 |
| Open | $1.85 |
| Day High | $1.89 |
| Day Low | $1.72 |
| Volume | 49,694 |
Stock Information
| Shares Outstanding | 1.77M |
| Total Debt | $58K |
| Cash Equivalents | $11.05M |
| Net Income | $-10.91M |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | $3.29M |
| P/E Ratio | 0.05 |
| EPS (TTM) | $38.89 |
| Exchange | NCM |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $-7.70M |
| Income | $-10.91M |
| Book/sh | $6.65 |
| Cash/sh | $6.24 |
| Employees | 3 |
Financial Ratios
| Quick Ratio | 13.91 |
| Current Ratio | 14.21 |
| Debt/Eq | 0.55 |
Returns & Margins
| ROA | -88.82% |
| ROE | -185.67% |
Ownership
| Insider Ownership | 0.46% |
| Institutional Ownership | 2.80% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| Forward P/E | -0.73 |
| P/B | 0.28 |
Analyst Data
| Recommendation | none |
| Target Price | $21.00 |
Technical Indicators
| SMA20 | $2.11 |
| SMA50 | $2.23 |
| SMA200 | $20.29 |
| RSI | 44.60 |
| ATR | 0.1891 |
| Shares Float | 1.77M |
| Short Float | 6.98% |
| Short Ratio | 3.60 |
| Volatility | -0.66 |
| Rel Volume | 0.43 |
Performance History
| Week | -18.78% |
| Month | -15.45% |
| Quarter | -28.19% |
| 6 Months | -82.05% |
| YTD | -76.28% |
| Year | -94.97% |
| 3 Years | -100.00% |
| 5 Years | -100.00% |
| 10 Years | -100.00% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-06-23 | $1.86 | 49,800 |
| 2026-06-22 | $1.87 | 53,100 |
| 2026-06-18 | $1.88 | 642,800 |
| 2026-06-17 | $2.32 | 650,000 |
| 2026-06-16 | $2.17 | 17,800 |
| 2026-06-15 | $2.29 | 29,500 |
| 2026-06-12 | $2.25 | 51,000 |
| 2026-06-11 | $2.31 | 71,700 |
| 2026-06-10 | $2.31 | 98,100 |
| 2026-06-09 | $2.20 | 73,400 |
| 2026-06-08 | $2.17 | 235,800 |
| 2026-06-05 | $2.00 | 17,200 |
| 2026-06-04 | $2.13 | 40,100 |
| 2026-06-03 | $2.01 | 39,600 |
| 2026-06-02 | $2.01 | 32,000 |
| 2026-06-01 | $2.07 | 48,100 |
| 2026-05-29 | $2.06 | 31,700 |
| 2026-05-28 | $2.10 | 42,900 |
| 2026-05-27 | $2.10 | 80,000 |
| 2026-05-26 | $2.04 | 31,700 |
About GRI Bio, Inc.
GRI Bio, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing therapies that target diseases leading to inflammatory, fibrotic, and autoimmune disorders in the United States. Its lead product candidate is GRI-0621, an oral inhibitor of type 1 Natural Killer T cells, which is in phase IIa clinical trial for the treatment of severe fibrotic lung diseases, such as idiopathic pulmonary fibrosis. The company's portfolio also includes GRI-0803, a novel oral agonist of type 2 Natural Killer T cells that is in preclinical development for the treatment of autoimmune disorders; a proprietary library of 500+ compounds; and GRI-0124 and GRI-0729 for balance inflammatory immune responses. The company was formerly known as Glycoregimmune, Inc. GRI Bio, Inc. was founded in 2009 and is based in LA Jolla, California.
đ° Latest News
How The Grainger (LSE:GRI) Investment Story Is Evolving As The Narrative Holds Steady
Simply Wall St. âĸ 2026-04-04T16:11:46Z
3 Undervalued Small Caps In Global With Recent Insider Activity
Simply Wall St. âĸ 2026-04-02T09:40:01Z
Sector Update: Health Care Stocks Climb Late Afternoon
MT Newswires âĸ 2025-09-11T19:49:40ZSector Update: Health Care Stocks Higher Thursday Afternoon
MT Newswires âĸ 2025-09-11T17:29:04ZGRI Bio reports six-week interim safety outcomes from trial of GRI-0621 for IPF
Clinical Trials Arena âĸ 2025-06-30T14:54:57Z
Period:
Loading...
Income Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Revenue | ||||
| Total Revenue | $0 | $0 | $0 | $0 |
| Operating Revenue | $0 | $0 | $0 | $0 |
| Expenses | ||||
| Total Expenses | $11,977,000 | $8,235,000 | $11,387,000 | $2,239,000 |
| Net Non Operating Interest Income Expense | $21,000 | $25,000 | $-2,082,000 | $-653,000 |
| Operating Expense | $11,977,000 | $8,235,000 | $11,387,000 | $2,239,000 |
| General And Administrative Expense | $5,158,000 | $4,467,000 | $8,155,000 | $1,997,000 |
| Other Income Expense | - | $3,000 | $432,000 | $-325,000 |
| Other Non Operating Income Expenses | - | $3,000 | $432,000 | - |
| Interest Expense | - | - | $2,082,000 | $653,000 |
| Interest Expense Non Operating | - | - | $2,082,000 | $653,000 |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $-11,956,000 | $-8,207,000 | $-13,037,000 | $-3,217,000 |
| Net Interest Income | $21,000 | $25,000 | $-2,082,000 | $-653,000 |
| Interest Income | $21,000 | $25,000 | - | - |
| Normalized Income | $-11,956,000 | $-8,207,000 | $-13,037,000 | $-2,892,000 |
| Net Income From Continuing And Discontinued Operation | $-11,956,000 | $-8,207,000 | $-13,037,000 | $-3,217,000 |
| Total Operating Income As Reported | $-11,977,000 | $-8,235,000 | $-11,387,000 | $-2,239,000 |
| Net Income Common Stockholders | $-11,956,000 | $-10,118,000 | $-13,037,000 | $-3,217,000 |
| Net Income | $-11,956,000 | $-8,207,000 | $-13,037,000 | $-3,217,000 |
| Net Income Including Noncontrolling Interests | $-11,956,000 | $-8,207,000 | $-13,037,000 | $-3,217,000 |
| Net Income Continuous Operations | $-11,956,000 | $-8,207,000 | $-13,037,000 | $-3,217,000 |
| Pretax Income | $-11,956,000 | $-8,207,000 | $-13,037,000 | $-3,217,000 |
| Interest Income Non Operating | $21,000 | $25,000 | - | - |
| Operating Income | $-11,977,000 | $-8,235,000 | $-11,387,000 | $-2,239,000 |
| Special Income Charges | - | - | $0 | $-325,000 |
| Per Share | ||||
| Diluted EPS | $-121.80 | $-1545.55 | $-125355.77 | $-47308.82 |
| Basic EPS | $-121.80 | $-1545.55 | $-125355.77 | $-47308.82 |
| Other | ||||
| Tax Effect Of Unusual Items | $0 | $0 | $0 | $0 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $-11,973,000 | $-8,231,000 | $-10,951,000 | $-2,236,000 |
| Reconciled Depreciation | $4,000 | $4,000 | $4,000 | $3,000 |
| EBITDA (Bullshit earnings) | $-11,973,000 | $-8,231,000 | $-10,951,000 | $-2,561,000 |
| EBIT | $-11,977,000 | $-8,235,000 | $-10,955,000 | $-2,564,000 |
| Diluted Average Shares | $98,161 | $6,546 | $104 | $68 |
| Basic Average Shares | $98,161 | $6,546 | $104 | $68 |
| Diluted NI Availto Com Stockholders | $-11,956,000 | $-10,118,000 | $-13,037,000 | $-3,217,000 |
| Otherunder Preferred Stock Dividend | $0 | $1,911,000 | - | - |
| Research And Development | $6,819,000 | $3,768,000 | $3,232,000 | $242,000 |
| Selling General And Administration | $5,158,000 | $4,467,000 | $8,155,000 | $1,997,000 |
| Other Gand A | $5,158,000 | $4,467,000 | $8,155,000 | $1,997,000 |
| Total Unusual Items | - | - | $182,000 | $-325,000 |
| Total Unusual Items Excluding Goodwill | - | - | $182,000 | $-325,000 |
| Gain On Sale Of Security | - | - | $182,000 | - |
| Other Special Charges | - | - | - | $325,000 |
Fetched: 2026-06-22
Balance Sheet (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $6,008,000 | $4,032,000 | $259,000 | $-1,625,000 |
| Total Assets | $8,666,000 | $5,739,000 | $2,956,000 | $383,000 |
| Total Non Current Assets | $74,000 | $124,000 | $22,000 | $71,000 |
| Current Assets | $8,592,000 | $5,615,000 | $2,934,000 | $312,000 |
| Other Current Assets | $363,000 | $587,000 | $1,126,000 | $303,000 |
| Cash Cash Equivalents And Short Term Investments | $8,229,000 | $5,028,000 | $1,808,000 | $9,000 |
| Cash And Cash Equivalents | $8,229,000 | $5,028,000 | $1,808,000 | $9,000 |
| Cash Financial | $8,229,000 | $5,028,000 | $1,808,000 | $9,000 |
| Non Current Prepaid Assets | - | - | - | $4,000 |
| Debt | ||||
| Total Debt | $71,000 | $119,000 | $14,000 | $673,000 |
| Long Term Debt And Capital Lease Obligation | $15,000 | $71,000 | $0 | $14,000 |
| Current Debt And Capital Lease Obligation | $56,000 | $48,000 | $14,000 | $659,000 |
| Net Debt | - | - | - | $593,000 |
| Current Debt | - | - | - | $602,000 |
| Other Current Borrowings | - | - | - | - |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $2,658,000 | $1,707,000 | $2,697,000 | $2,008,000 |
| Total Non Current Liabilities Net Minority Interest | $15,000 | $71,000 | $0 | $14,000 |
| Current Liabilities | $2,643,000 | $1,636,000 | $2,697,000 | $1,994,000 |
| Payables And Accrued Expenses | $2,587,000 | $1,588,000 | $2,680,000 | $1,330,000 |
| Payables | $1,837,000 | $897,000 | $1,410,000 | $1,294,000 |
| Accounts Payable | $1,837,000 | $897,000 | $1,410,000 | $1,294,000 |
| Other Current Liabilities | - | - | $3,000 | - |
| Current Deferred Liabilities | - | - | $0 | $5,000 |
| Current Notes Payable | - | - | $0 | $602,000 |
| Interest Payable | - | - | - | $0 |
| Equity | ||||
| Common Stock Equity | $6,008,000 | $4,032,000 | $259,000 | $-1,625,000 |
| Total Equity Gross Minority Interest | $6,008,000 | $4,032,000 | $259,000 | $-1,625,000 |
| Stockholders Equity | $6,008,000 | $4,032,000 | $259,000 | $-1,625,000 |
| Retained Earnings | $-51,696,000 | $-39,740,000 | $-31,533,000 | $-18,496,000 |
| Other | ||||
| Ordinary Shares Number | $497,692 | $18,767 | $104 | $68 |
| Share Issued | $497,692 | $18,767 | $104 | $68 |
| Tangible Book Value | $6,008,000 | $4,032,000 | $259,000 | $-1,625,000 |
| Invested Capital | $6,008,000 | $4,032,000 | $259,000 | $-1,023,000 |
| Working Capital | $5,949,000 | $3,979,000 | $237,000 | $-1,682,000 |
| Capital Lease Obligations | $71,000 | $119,000 | $14,000 | $71,000 |
| Total Capitalization | $6,008,000 | $4,032,000 | $259,000 | $-1,625,000 |
| Additional Paid In Capital | $57,704,000 | $43,772,000 | $31,792,000 | $16,871,000 |
| Capital Stock | $0 | $0 | $0 | $0 |
| Common Stock | $0 | $0 | $0 | $0 |
| Long Term Capital Lease Obligation | $15,000 | $71,000 | $0 | $14,000 |
| Current Capital Lease Obligation | $56,000 | $48,000 | $14,000 | $57,000 |
| Current Accrued Expenses | $750,000 | $691,000 | $1,270,000 | $36,000 |
| Net PPE | $74,000 | $124,000 | $22,000 | $71,000 |
| Accumulated Depreciation | $-34,000 | $-30,000 | $-26,000 | $-22,000 |
| Gross PPE | $108,000 | $154,000 | $48,000 | $93,000 |
| Other Properties | $71,000 | $120,000 | $14,000 | $67,000 |
| Machinery Furniture Equipment | $37,000 | $34,000 | $34,000 | $26,000 |
| Pensionand Other Post Retirement Benefit Plans Current | - | - | - | $33,000 |
Fetched: 2026-06-22
Cash Flow Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $-10,189,000 | $-8,611,000 | $-8,998,000 | $-1,088,000 |
| Operating Activities | ||||
| Operating Cash Flow | $-10,186,000 | $-8,611,000 | $-8,990,000 | $-1,085,000 |
| Cash Flow From Continuing Operating Activities | $-10,186,000 | $-8,611,000 | $-8,990,000 | $-1,085,000 |
| Operating Gains Losses | - | $-3,000 | $-182,000 | $325,000 |
| Investing Activities | ||||
| Capital Expenditure | $-3,000 | - | $-8,000 | $-3,000 |
| Investing Cash Flow | $-3,000 | $0 | $-8,000 | $-3,000 |
| Cash Flow From Continuing Investing Activities | $-3,000 | $0 | $-8,000 | $-3,000 |
| Financing Activities | ||||
| Repurchase Of Capital Stock | $-1,000 | $-1,000 | $0 | $-124,000 |
| Issuance Of Capital Stock | $15,560,000 | $13,103,000 | $12,250,000 | $0 |
| Financing Cash Flow | $13,390,000 | $11,831,000 | $10,797,000 | $1,007,000 |
| Cash Flow From Continuing Financing Activities | $13,390,000 | $11,831,000 | $10,797,000 | $1,007,000 |
| Net Other Financing Charges | $-2,169,000 | $-2,033,000 | $-2,715,000 | $-119,000 |
| Net Common Stock Issuance | $15,559,000 | $13,102,000 | $12,250,000 | $-124,000 |
| Common Stock Issuance | $15,560,000 | $13,103,000 | $12,250,000 | $0 |
| Other | ||||
| End Cash Position | $8,229,000 | $5,028,000 | $1,808,000 | $9,000 |
| Beginning Cash Position | $5,028,000 | $1,808,000 | $9,000 | $90,000 |
| Changes In Cash | $3,201,000 | $3,220,000 | $1,799,000 | $-81,000 |
| Proceeds From Stock Option Exercised | $0 | $762,000 | $12,000 | $0 |
| Common Stock Payments | $-1,000 | $-1,000 | $0 | $-124,000 |
| Net PPE Purchase And Sale | $-3,000 | $0 | $-8,000 | $-3,000 |
| Purchase Of PPE | $-3,000 | $0 | $-8,000 | $-3,000 |
| Change In Working Capital | $925,000 | $-448,000 | $1,680,000 | $1,515,000 |
| Change In Other Current Liabilities | $-48,000 | $105,000 | $-57,000 | $-43,000 |
| Change In Payables And Accrued Expense | $722,000 | $-866,000 | $2,284,000 | $1,593,000 |
| Change In Accrued Expense | $59,000 | $-479,000 | $125,000 | $696,000 |
| Change In Payable | $663,000 | $-387,000 | $2,159,000 | $897,000 |
| Change In Account Payable | $663,000 | $-387,000 | $2,159,000 | $897,000 |
| Change In Prepaid Assets | $251,000 | $313,000 | $-547,000 | $-35,000 |
| Other Non Cash Items | $48,000 | $-105,000 | $2,157,000 | $217,000 |
| Stock Based Compensation | $793,000 | $148,000 | $388,000 | $25,000 |
| Depreciation Amortization Depletion | $4,000 | $4,000 | $4,000 | $3,000 |
| Depreciation And Amortization | $4,000 | $4,000 | $4,000 | $3,000 |
| Depreciation | $4,000 | $4,000 | $4,000 | $3,000 |
| Net Income From Continuing Operations | $-11,956,000 | $-8,207,000 | $-13,037,000 | $-3,217,000 |
| Issuance Of Debt | - | $0 | $1,250,000 | $1,500,000 |
| Net Issuance Payments Of Debt | - | $0 | $1,250,000 | $1,250,000 |
| Net Short Term Debt Issuance | - | $0 | $1,250,000 | $1,250,000 |
| Short Term Debt Issuance | - | $0 | $1,250,000 | $1,500,000 |
| Gain Loss On Investment Securities | - | $-3,000 | $-182,000 | - |
| Repayment Of Debt | - | - | $0 | $-250,000 |
| Interest Paid Supplemental Data | - | - | $0 | $33,000 |
| Short Term Debt Payments | - | - | $0 | $-250,000 |
| Asset Impairment Charge | - | - | $53,000 | $47,000 |
| Net Long Term Debt Issuance | - | - | - | $1,250,000 |
| Long Term Debt Payments | - | - | - | $-125,000 |
| Long Term Debt Issuance | - | - | - | $1,375,000 |
Fetched: 2026-06-22